Chronic statin-use before PCI in acute coronary syndromes and in-hospital outcomes: ACCNCDR registry in India

IF 4.3 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Rajeev Gupta , Prashant Dwivedi , Krishna K Sharma , Sanjeev K Sharma , Jitender S Makkar , Atul Kasliwal , Vishnu Natani , Raghubir S Khedar , Samin K Sharma , Soneil Guptha
{"title":"Chronic statin-use before PCI in acute coronary syndromes and in-hospital outcomes: ACCNCDR registry in India","authors":"Rajeev Gupta ,&nbsp;Prashant Dwivedi ,&nbsp;Krishna K Sharma ,&nbsp;Sanjeev K Sharma ,&nbsp;Jitender S Makkar ,&nbsp;Atul Kasliwal ,&nbsp;Vishnu Natani ,&nbsp;Raghubir S Khedar ,&nbsp;Samin K Sharma ,&nbsp;Soneil Guptha","doi":"10.1016/j.ajpc.2025.100999","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To compare in-hospital major cardiovascular adverse outcomes among chronic statin-user and statin-naïve acute coronary syndrome(ACS) patients following percutaneous coronary intervention(PCI).</div></div><div><h3>Methods</h3><div>Successive patients with ACS who underwent PCI from Sep’17 to Dec’23 were enrolled in a prospective registry. Details of risk factors, presentation, angiography, interventions, and in-hospital outcomes were recorded. Chronic statin use was defined as &gt; 1-month intake before presentation. Primary outcomes were in-hospital all-cause and cardiovascular deaths. Univariate and multivariate odds ratios(OR) and 95 % confidence intervals(CI) were calculated.</div></div><div><h3>Results</h3><div>8296 patients were enrolled, and ACS was in 7892(STEMI-ST elevation myocardial infarction 3222, non-STEMI/unstable angina 4670). Prior chronic statin use was in 2949(37.4 %), and 4943(62.6 %) were statin naïve. Statin-user vs. statin-naïve patients were older(62±10 vs. 60±11y), with more hypertension(61 vs. 48 %), diabetes(36 vs. 32 %), prior PCI(20 vs 8 %), CABG(5 vs 2 %), beta-blockers(61.7 vs 8.3 %), anti-platelets(92.8 vs 5.3 %), and lower mean total-, LDL-, and non-HDL-cholesterol(<em>p</em> &lt; 0.001); chronic statin users had less STEMI(30 % vs 47 %) and better LVEF(46.5 ± 10 vs 44.5 ± 10 %) at presentation and median hospitalization was shorter(66.3 vs 68.6 h)(<em>p</em> &lt; 0.001). In statin-user vs. statin-naïve groups, the incidence of all-cause deaths: 33(1.12 %) vs 85(1.72 %) (OR 0.65, CI 0.43–0.97) and CV deaths: in 29(0.98 %) vs 73(1.47 %) (OR 0.67, CI 0.43–1.02) were lower. The ORs attenuated following multivariate adjustments for risk factors, previous treatments, clinical features, angiographic findings and interventions.</div></div><div><h3>Conclusions</h3><div>Acute coronary syndrome patients taking pre-admission statins and other cardioprotective medicines have lower in-hospital all-cause deaths. This is associated with less STEMI, better LVEF, and shorter hospitalization in prior statin users.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"22 ","pages":"Article 100999"},"PeriodicalIF":4.3000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of preventive cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666667725000741","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

To compare in-hospital major cardiovascular adverse outcomes among chronic statin-user and statin-naïve acute coronary syndrome(ACS) patients following percutaneous coronary intervention(PCI).

Methods

Successive patients with ACS who underwent PCI from Sep’17 to Dec’23 were enrolled in a prospective registry. Details of risk factors, presentation, angiography, interventions, and in-hospital outcomes were recorded. Chronic statin use was defined as > 1-month intake before presentation. Primary outcomes were in-hospital all-cause and cardiovascular deaths. Univariate and multivariate odds ratios(OR) and 95 % confidence intervals(CI) were calculated.

Results

8296 patients were enrolled, and ACS was in 7892(STEMI-ST elevation myocardial infarction 3222, non-STEMI/unstable angina 4670). Prior chronic statin use was in 2949(37.4 %), and 4943(62.6 %) were statin naïve. Statin-user vs. statin-naïve patients were older(62±10 vs. 60±11y), with more hypertension(61 vs. 48 %), diabetes(36 vs. 32 %), prior PCI(20 vs 8 %), CABG(5 vs 2 %), beta-blockers(61.7 vs 8.3 %), anti-platelets(92.8 vs 5.3 %), and lower mean total-, LDL-, and non-HDL-cholesterol(p < 0.001); chronic statin users had less STEMI(30 % vs 47 %) and better LVEF(46.5 ± 10 vs 44.5 ± 10 %) at presentation and median hospitalization was shorter(66.3 vs 68.6 h)(p < 0.001). In statin-user vs. statin-naïve groups, the incidence of all-cause deaths: 33(1.12 %) vs 85(1.72 %) (OR 0.65, CI 0.43–0.97) and CV deaths: in 29(0.98 %) vs 73(1.47 %) (OR 0.67, CI 0.43–1.02) were lower. The ORs attenuated following multivariate adjustments for risk factors, previous treatments, clinical features, angiographic findings and interventions.

Conclusions

Acute coronary syndrome patients taking pre-admission statins and other cardioprotective medicines have lower in-hospital all-cause deaths. This is associated with less STEMI, better LVEF, and shorter hospitalization in prior statin users.

Abstract Image

急性冠状动脉综合征PCI前慢性他汀类药物使用和住院结果:印度ACCNCDR登记
目的 比较经皮冠状动脉介入治疗(PCI)后长期使用他汀类药物和未使用他汀类药物的急性冠状动脉综合征(ACS)患者的院内主要心血管不良预后。方法 将 17 年 9 月至 23 年 12 月期间接受 PCI 治疗的急性冠状动脉综合征(ACS)患者纳入前瞻性登记。详细记录了危险因素、发病情况、血管造影、介入治疗和院内预后。他汀类药物的长期使用定义为发病前1个月内服用他汀类药物。主要结果是院内全因死亡和心血管死亡。计算了单变量和多变量几率比(OR)及95%置信区间(CI)。结果 8296名患者入选,其中ACS患者7892名(STEMI-ST段抬高型心肌梗死3222名,非STEMI/不稳定型心绞痛4670名)。2949人(37.4%)曾长期使用他汀类药物,4943人(62.6%)未使用过他汀类药物。使用他汀与未使用他汀的患者年龄更大(62±10 岁 vs. 60±11岁),高血压(61% vs. 48%)、糖尿病(36% vs. 32%)、PCI(20% vs. 8%)、CABG(5% vs. 2%)、β-受体阻滞剂(61.7% vs. 8.3%)、抗血小板药物(92.8% vs. 5.他汀类药物长期使用者的 STEMI(30% vs 47%)较少,发病时 LVEF(46.5 ± 10 vs 44.5 ± 10%)较好,中位住院时间较短(66.3 vs 68.6 h)(p < 0.001)。使用他汀类药物组与未使用他汀类药物组相比,全因死亡发生率较低:33(1.12%) vs 85(1.72%)(OR 0.65,CI 0.43-0.97),冠心病死亡发生率较低:29(0.98%) vs 73(1.47%)(OR 0.67,CI 0.43-1.02)。在对风险因素、既往治疗、临床特征、血管造影结果和干预措施进行多变量调整后,OR 值有所降低。结论入院前服用他汀类药物和其他心脏保护药物的急性冠状动脉综合征患者的院内全因死亡率较低,这与他汀类药物使用者STEMI较少、LVEF较好和住院时间较短有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American journal of preventive cardiology
American journal of preventive cardiology Cardiology and Cardiovascular Medicine
CiteScore
6.60
自引率
0.00%
发文量
0
审稿时长
76 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信